RVSV-EBOV: Phase I resumed

The University Hospitals of Geneva resumed a double-blind, placebo-controlled, Swiss Phase I trial of VSV-ZEBOV in 115 healthy volunteers. The trial was put on hold last month due to volunteers complaining of mild joint pain in the hands and feet 10-15 days after an injection. The trial will now enroll the remaining 56 volunteers and use a lower dose containing 300,000 vaccine particles. The study previously used doses containing 10 and 50 million vaccine particles. The hospital said 10 volunteers had experienced joint inflammation that was induced by the vaccinations but the symptoms “quickly” disappeared. ...